<table id="_Refid_2aaeba04-be08-484e-92a8-c3e305d52" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 11. Development of Resistance to Maraviroc or Efavirenz and Background Drugs in Antiretroviral Treatment-Naive Trial A4001026 for Patients with CCR5-Tropic Virus at Screening Using Enhanced Sensitivity TROFILE<sup>Â®</sup> Assay</caption>
<col span="1" width="74%"></col>
<col span="1" width="12%"></col>
<col span="1" width="11%"></col>
<tbody>
<tr>
<td></td>
<td>
<paragraph>Maraviroc</paragraph>
</td>
<td>
<paragraph>Efavirenz</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Total N in dataset (as-treated)</paragraph>
</td>
<td>
<paragraph>273</paragraph>
</td>
<td>
<paragraph>241</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Total virologic failures (as-treated)</paragraph>
</td>
<td>
<paragraph>85 (31%)</paragraph>
</td>
<td>
<paragraph>56 (23%)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Evaluable virologic failures with post baseline genotypic and phenotypic data</paragraph>
</td>
<td>
<paragraph>73</paragraph>
</td>
<td>
<paragraph>43</paragraph>
</td>
</tr>
<tr>
<td>
<list listtype="unordered">
<item>Lamivudine resistance</item>
</list>
</td>
<td>
<paragraph>39 (53%)</paragraph>
</td>
<td>
<paragraph>13 (30%)</paragraph>
</td>
</tr>
<tr>
<td>
<list listtype="unordered">
<item>Zidovudine resistance</item>
</list>
</td>
<td>
<paragraph>2 (3%)</paragraph>
</td>
<td>
<paragraph>0</paragraph>
</td>
</tr>
<tr>
<td>
<list listtype="unordered">
<item>Efavirenz resistance</item>
</list>
</td>
<td>
<paragraph>--</paragraph>
</td>
<td>
<paragraph>23 (53%)</paragraph>
</td>
</tr>
<tr>
<td>
<list listtype="unordered">
<item>Phenotypic resistance to maraviroc<sup>a</sup>
</item>
</list>
</td>
<td>
<paragraph>19 (26 % )</paragraph>
</td>
<td></td>
</tr>
</tbody>
</table>